Vical: Vaxfectin-formulated Measles DNA vaccine elicits long-term protection and sterilizing immunity in nonhuman primates

Co announces that a measles DNA vaccine formulated with the co's Vaxfectin adjuvant elicited protective levels of neutralizing antibodies in juvenile (1-2 year old) nonhuman primates confirmed by complete protection following challenge more than one year after vaccination, and sterilizing immunity as evidenced by no clinical signs of disease and no detectable virus after challenge. In a separate study, the same vaccine elicited protective levels of neutralizing antibodies in infant (6-10 weeks old) nonhuman primates with no vaccine-related adverse events. The studies were conducted in collaboration with Diane Griffin, M.D., Ph.D., Alfred and Jill Sommer Professor and Chair of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, under a grant from the Bill and Melinda Gates Foundation.

• Tweet this
• Link this
• Share this
• Digg this
• Email
• Reprints

Comments (0)

This discussion is now closed. We welcome comments on our articles for a limited period after their publication.